Epidemiological Features of NAFLD From 1999 to 2018 in China

Abstract

With dramatic changes in lifestyles over the last 20 years, nonalcoholic fatty liver disease (NaFlD) has become the most prevalent liver disorder in China but has not received sufficient attention. NaFlD-related advanced liver disease and its mortality along with its overall disease burden are expected to increase substantially. there is thus an imperative need to clarify the epidemiological features of NaFlD to guide a holistic approach to management. We summarize eight epidemiological features of NaFlD in China over the past two decades using systematic review and meta-analysis methodology. our data reveal a rapid growth in the NaFlD population, especially among younger individuals. Importantly, there is a strong ethnic difference in body mass index (BMI) and genetic risk of NaFlD compared with the US population. the etiology of advanced liver disease and its complications (e.g., hepatocellular carcinoma) has been altered because of a Westernized lifestyle and the implementation of effective vaccination strategies against viral hepatitis. Regional epidemiological patterns of NaFlD indicate that economics, environment, and lifestyle are critical factors in disease progression. the analysis also indicates that a large number of patients remain undiagnosed and untreated because of the inadequacy of diagnostic tools and the absence of effective pharmacologic therapies. given the burden of NaFlD, future policy and research efforts need to address knowledge gaps to mitigate the risk burden.

Longitudinal Association Between Markers of Liver Injury and Mortality in COVID‐19 in China

“…Only 81 patients recorded a history of chronic liver disease (4 with nonalcoholic fatty liver disease and 77 with viral hepatitis), which are much lower than the prevalence in China. ( 20,21 ) We are unable to assess whether coexistence of chronic liver comorbidities increases susceptibility to liver injury in SARS‐CoV‐2 infection. Previous studies have shown that SARS‐CoV‐2 may aggravate liver injury in patients with viral hepatitis.…”

Efficacy of serum miRNA test as a non-invasive method to diagnose nonalcoholic steatohepatitis: a systematic review and meta-analysis.

“…In developed countries such as the United States, the prevalence of NAFLD is 30% [1]. In developing countries such as China, the prevalence has reached up to 32.9% [2]. NAFLD comprises a spectrum of pathological conditions, including simple steatosis (NAFL), nonalcoholic steatohepatitis (NASH), brosis, cirrhosis and hepatocellular carcinoma (HCC).…”

“…The pooled values of NASH trials were as follows: sensitivity = 0.74 (95% CI: 0.66-0.81) I 2 = 74.94%; speci city = 0.85 (95% CI: 0.77-0.91) I2 = 79.60%; PLR = 5.01 (95% CI: 3.11-8.05); NLR = 0.31 (95% CI: 0.23-0.42); DOR = 16.24 (95% CI: 8.17-32.28); and AUROC = 0.86 (95% CI: 0.83-0.89) (Additional le 1: Fig S5). (2) The pooled values of NAFLD trials were as follows: sensitivity = 0.71 (95% CI: 0.58-0.81) I 2 = 96.88%; speci city = 0.76 (95% CI: 0.68-0.83) I 2 = 90.57%; PLR = 2.99 (95% CI: 2.24-3.99); NLR = 0.38 (95% CI: 0.26-0.55); DOR = 7.93 (95% CI: 4.66-13.49); and AUROC = 0.80 (95% CI: 0.77-0.84) (Additional le 1: Fig S6).…”

Chronic HBV Infection Associates with Improvement of Lipid Profile and Steatosis-Related Impairment in Nonalcoholic Fatty Liver Disease: A Lipidomic Analysis

“…Recent decades have witnessed the rapid growing incidence of nonalcoholic fatty liver disease (NAFLD), a metabolic stress-induced chronic liver disease, in China by the prevalence of overweight/obesity and/or sedentary lifestyle [9,10]. In result, concurrent NAFLD is now identi ed in 13.5% (12/ 91) and 14% (260/ 1915) chronic hepatitis B infection patients from Hong Kong (China) and Hang Zhou (Zhe Jiang, China), respectively [7,11].…”